(Q37674956)

21 August 2017

0 references

1 reference

title

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials (English)

1 reference

21 August 2017

0 references

1 reference

Sashidhar V Sagi

1

1 reference

21 August 2017

Sahil Mittal

series ordinal

2

1 reference

21 August 2017

Krishna S Kasturi

series ordinal

3

1 reference

21 August 2017

Gagan K Sood

series ordinal

4

1 reference

21 August 2017

14 January 2010

1 reference

Journal of Gastroenterology and Hepatology

21 August 2017

1 reference

21 August 2017

25

1 reference

21 August 2017

5

1 reference

21 August 2017

880-885

1 reference

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

21 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Effects of continuous vasopressin infusion in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Pathogenesis and treatment of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Meta-analysis: terlipressin therapy for the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06132.X

10.1111/J.1440-1746.2009.06132.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference